FOXO Technologies (FOXO)
OTHER OTC:FOXO
Top Page
FOXO Technologies
(OTC:FOXO)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.01
▲(0.00% Upside)
Action:ReiteratedDate:01/21/26
The score is primarily held back by persistent losses and continued operating/free-cash-flow burn despite improving revenue and gross margin trends. Corporate events add mixed impact (operational progress but higher dilution risk), while valuation remains constrained by negative earnings and technicals cannot be substantiated from the missing indicator set.
Positive Factors
Revenue Growth
FOXO's significant revenue growth indicates strong market demand and potential for scaling its innovative health solutions, enhancing long-term business prospects.
Negative Factors
High Debt Levels
High debt levels pose a risk to financial stability, potentially limiting FOXO's ability to invest in growth opportunities and manage economic downturns effectively.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
FOXO's significant revenue growth indicates strong market demand and potential for scaling its innovative health solutions, enhancing long-term business prospects.
Read all positive factors
FOXO Technologies (FOXO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$306.27K
Dividend YieldN/A
Average Volume (3M)10.82M
Price to Earnings (P/E)―
Beta (1Y)72.11
Revenue Growth1049.89%
EPS Growth66.27%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,062,661,000
10 Day Avg. Volume5,970,242
30 Day Avg. Volume10,822,142
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)14.54
Price to Sales (P/S)19.10
P/FCF Ratio-27.25
Enterprise Value/Market Cap30.78
Enterprise Value/Revenue0.64
Enterprise Value/Gross Profit1.37
Enterprise Value/Ebitda-2.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FOXO Technologies Business Overview & Revenue Model
Company Description
FOXO Technologies Inc., a technology platform company, focuses on commercializing longevity science through products and services that serve the life insurance industry. The company is developing products and services that combine longevity scienc...
How the Company Makes Money
FOXO Technologies generates revenue through a combination of direct-to-consumer sales and B2B partnerships. The company offers epigenetic testing services directly to consumers, allowing individuals to gain insights into their biological age and w...
FOXO Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.76M | 4.05M | 145.29K | 511.00K | 120.00K | 63.00K |
| Gross Profit | 6.90M | 1.57M | 12.86K | 167.00K | 120.00K | 63.00K |
| EBITDA | -4.15M | -7.28M | -24.11M | -92.30M | -37.27M | -7.46M |
| Net Income | -9.81M | -12.41M | -26.45M | -95.25M | -38.49M | -8.65M |
Balance Sheet | ||||||
| Total Assets | 52.09M | 41.71M | 725.00K | 35.41M | 30.30M | 9.42M |
| Cash, Cash Equivalents and Short-Term Investments | 628.56K | 68.27K | 38.00K | 5.51M | 6.86M | 8.12M |
| Total Debt | 10.05M | 14.25M | 4.20M | 3.14M | 32.20M | 0.00 |
| Total Liabilities | 31.96M | 36.44M | 14.82M | 28.70M | 55.52M | 704.00K |
| Stockholders Equity | 20.20M | 5.32M | -14.10M | 6.71M | -25.22M | 8.72M |
Cash Flow | ||||||
| Free Cash Flow | -5.74M | -2.84M | -6.64M | -25.63M | -15.30M | -481.42K |
| Operating Cash Flow | -5.61M | -2.84M | -6.64M | -23.76M | -15.05M | -481.43K |
| Investing Cash Flow | -637.54K | 13.33K | 0.00 | -1.87M | -355.00K | -201.25M |
| Financing Cash Flow | 6.84M | 2.86M | 1.17M | 24.29M | 14.14M | 203.20M |
FOXO Technologies Technical Analysis
Negative
0.01
Price Trends
0.25
Negative
0.92
Negative
3.60
Negative
Market Momentum
-0.09
Negative
16.55
Positive
2.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOXO, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.25, and below the 200-day MA of 3.60, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 16.55 is Positive, neither overbought nor oversold. The STOCH value of 2.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FOXO.
FOXO Technologies Risk Analysis
FOXO Technologies disclosed 53 risk factors in its most recent earnings report. FOXO Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
FOXO Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $306.27K | -0.02 | -80.11% | ― | 1049.89% | 66.27% | |
44 Neutral | $47.25M | -3.85 | -571.06% | ― | ― | 4.31% | |
42 Neutral | $10.89M | -0.51 | 336.68% | ― | 187.24% | 82.90% | |
41 Neutral | $2.77M | >-0.01 | -112.81% | ― | -21.88% | 68.40% |
* Healthcare Sector Average
FOXO
FOXO Technologies
0.01
-2.25
-99.56%
HCTI
Healthcare Triangle
2.40
-3,309.80
-99.93%
BEAT
HeartBeam
1.15
-0.53
-31.55%
EUDA
EUDA Health Holdings
6.72
-69.68
-91.20%
VSEE
VSee Health
0.23
-0.82
-78.01%
BFRG
BullFrog AI Holdings, Inc.
0.89
-1.22
-57.86%
FOXO Technologies Corporate Events
Business Operations and StrategyPrivate Placements and Financing
FOXO Technologies expands rural care with new tele-specialties
Positive
Jan 20, 2026
On January 18, 2026, FOXO Technologies increased its authorized common stock from 2.5 billion to 10 billion shares, a move that gives the company significantly more flexibility to raise capital, pursue corporate transactions, or support future gro...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
FOXO Technologies Expands Share Authorization and Preferred Terms
Positive
Dec 19, 2025
On December 16, 2025, FOXO Technologies amended the terms of its Series B and Series C cumulative convertible redeemable preferred stock, revising the conversion price formula to the higher of $0.0001 or 90% of the average volume-weighted average ...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresM&A Transactions
FOXO Technologies Announces Year-End Review by CEO
Positive
Dec 16, 2025
On December 15, 2025, FOXO Technologies Inc. announced a year-end review by CEO Seamus Lagan, highlighting significant milestones and strategic acquisitions in 2025. The company expanded its healthcare portfolio by acquiring Myrtle Recovery Center...
Business Operations and Strategy
FOXO Technologies’ Subsidiary Recognized for Community Impact
Positive
Dec 10, 2025
On December 9, 2025, FOXO Technologies announced that its subsidiary, Myrtle Recovery Centers, was recognized by the Rural Health Association of Tennessee for its significant community impact. This recognition highlights Myrtle’s success in ...
DividendsRegulatory Filings and Compliance
FOXO Technologies Amends Certificate for Preferred Stocks
Neutral
Nov 4, 2025
On October 29, 2025, FOXO Technologies Inc. amended its Certificate of Incorporation concerning its Series D and Series E Preferred Stocks. The amendment for Series D Preferred Stock revises the conversion price, while the Series E Preferred Stock...
Regulatory Filings and Compliance
FOXO Technologies Increases Authorized Shares Significantly
Neutral
Oct 23, 2025
FOXO Technologies Inc., a Delaware corporation, has increased its authorized shares of Common Stock from 500,000,000 to 2,500,000,000 shares. This amendment to the Certificate of Incorporation was filed with the Secretary of State of Delaware and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.